Mayo Clinic Ovarian Cancer SPORE

Investigators for the Ovarian Cancer SPORE focus their efforts on three major translational research projects. Within these projects, they are studying DNA topoisomerase 1 (TOP1) inhibitors, PARP inhibitors, ATR inhibitors, the use of natural killer (NK) cells as an adoptive cellular therapy for cancer, and the administration of a vaccine to prevent ovarian cancer recurrence in an effort to address unmet patient needs. 

• Project 1: Next-Generation TOP1 Inhibition To Treat Ovarian Cancer. 
• Project 2: Treating Advanced Ovarian Cancer Using Gene-Edited CAR NK Cells. 
• Project 4: Th17 T Cell-inducing Vaccines for the Prevention of Ovarian Cancer Recurrence. 

The SPORE applies an interdisciplinary approach to meet our objectives for research. Our investigators work together as a team to meet the goals of the SPORE, leveraging expertise in basic research, population science and clinical investigation. We also work with investigators from SPOREs and ovarian cancer research groups at other institutions in a collaborative effort to improve therapeutic outcomes.

Within the SPORE, four cores support all aspects of our research efforts, including leadership, specimens, statistical collaboration and research models. 

The SPORE also has two funding programs.These programs provide pilot project research funding and career development support to investigators, including new investigators and seasoned investigators who want to redirect their work to ovarian cancer.